FluoroPharma Medical, developer of advanced medical diagnostic imaging products, with a current focus on imaging agents for breakthrough positron emission tomography (PET) applications, obtains critical advice and guidance from a scientific advisory board made up of top experts in the … Continue reading →

FluoroPharma Medical, Inc., a company specializing in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, announced this morning that they have secured an additional … Continue reading →

In the developing high tech world of advanced medical technology, company leaders require a unique combination of technical vision, business acuity, and an in-depth knowledge of the special requirements associated with human health care. FluoroPharma Medical, developer of advanced diagnostic … Continue reading →

Today before the opening bell, FluoroPharma Medical announced that composition of matter patents covering AZPET, the company’s Alzheimer’s Disease agent, have been issued by the U.S. patent office expiring in 2028. FluoroPharma has also been granted patent rights in China … Continue reading →

Advanced imaging technologies are certainly among the most important developments in modern medicine. They’ve allowed us to view the workings of the human body as never before, allowing increasingly accurate up-front diagnosis without the cost, dangers, and discomfort involved in … Continue reading →

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products … Continue reading →

FluoroPharma Medical announced it has received subscriptions from select accredited investors for gross proceeds of $1.6 million in a private placement offering. The proceeds from this financing together with the previously announced financing in May 2011 aggregates $5.3 million. The … Continue reading →

In a reverse merger, Commercial E Waste Management (formerly traded under ticker symbol CEWM) recently acquired FluoroPharma Medical, a developer of proprietary PET imaging products. The newly formed company is now known as FluoroPharma Medical. Upon finalizing the transaction, FluoroPharma … Continue reading →

FluoroPharma Medical, a biopharmaceutical company developing the next generation proprietary PET imaging products, announced the change of its official stock ticker symbol from CEWM to FPMI. These changes are made in conjunction with the previously announced FluoroPharma Inc. merger with … Continue reading →

FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial … Continue reading →